Immunovant Sciences clinical trials
Immunovant Sciences is the lead sponsor of 9 current clinical trials in our UK, USA, Poland, Spain, Germany, Italy, Czechia, Australia, Netherlands, Belgium, Denmark, Brazil, Mexico, Canada, South Korea, Israel, Ireland, Austria, Norway, Portugal, Turkey, Japan and EU (CTIS) registers. 4 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are IMVT-1402. The most-studied condition is Graves' Disease.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Immunovant Sciences
8 on ClinicalTrials.govRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Immunovant Sciences in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System with Immunovant Sciences as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
2025-521920-31-00 · CTIS ↗ · Immune System Diseases
Drug: IMVT-1402 |
Phase 2 | Ongoing | Italy, Poland, Greece + 6 more |
Drugs in Immunovant Sciences trials
1 compoundDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Immunovant Sciences trials
7 conditionsBy trial register
A trial with sites in more than one country appears in each of those registers.
Questions about Immunovant Sciences trials
How many clinical trials does Immunovant Sciences sponsor?
Immunovant Sciences is the lead sponsor of 8 current trials on ClinicalTrials.gov in our UK, USA, Poland, Spain, Germany, Italy, Czechia, Australia, Netherlands, Belgium, Denmark, Brazil, Mexico, Canada, South Korea, Israel, Ireland, Austria, Norway, Portugal, Turkey and Japan registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are Immunovant Sciences trials recruiting?
Yes. 4 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Immunovant Sciences testing?
Its current trials name 1 drug or biological as interventions. The most frequent are IMVT-1402 (8). The number in brackets is how many of its trials name each drug.
Does Immunovant Sciences have clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.